JAMA · 1953 · 30 citations · 7 references
MedicineNuclear MedicineOncologyRadiobiologyRadionuclide TherapyTherapeutic Nuclear MedicineAscites ManagementMalignant NeoplasmsRadionuclide Therapy PrinciplesRadiopharmaceutical TherapyIntraperitoneal AdministrationMalignant AscitesMalignant Pleural EffusionPleural CavitiesPleural Effusion In MalignancySurgical Management Of Ascites
Since the majority of patients with cancer eventually succumb to their disease, the practicing physician frequently must deal with the problem of palliation. One of the complications of advanced cancer is the accumulation of fluid in the peritoneal or pleural cavities, which not only mechanically interferes with the function of the lungs and gastrointestinal tract but also depletes the body of proteins. Clark<sup>1</sup>reports a 29% incidence of significant effusions (over 1,000 cc. of fluid) in 266 consecutive autopsies on men with malignant disease. A radioactive isotope was first used to treat ascites due to peritoneal carcinomatosis by Muller in 1945, who used Zn<sup>63</sup>prepared in a cyclotron. In 1950<sup>2</sup>he reported on eight patients treated by intraperitoneal injection of colloidal Au<sup>198</sup>, including one in whom both intrapleural and intraperitoneal injections were performed. The inhibition of fluid formation noted in these patients has encouraged other clinical
7